Evidence map›Paper›PMID 35634422›Full record

ArticleLiver cancer2022

LIM Homeobox-2 Suppresses Hallmarks of Adult and Pediatric Liver Cancers by Inactivating MAPK/ERK and Wnt/Beta-Catenin Pathways.

Nicola Mosca, Fatma Zohra Khoubai, Sandrine Fedou, Juan Carrillo-Reixach, Stefano Caruso, Alvaro Del Rio-Alvarez, Emeric Dubois, Christophe Avignon, Nathalie Dugot-Senant, Catherine Guettier and 6 more

Open access · goldAbstract read
In one paragraph

Article in Liver cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. LHX3 promotes EMT in hepatoma cell through β-catenin/TCF4 pathway.Medical oncology (Northwood, London, England) · 2024
    Article
  8. Article
  9. Review
  10. Making Sense of Antisense lncRNAs in Hepatocellular Carcinoma.International journal of molecular sciences · 2023
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Nicola MoscaMIRCADE Team, Univ. Bordeaux, Inserm, BMGIC, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, U1035, Bordeaux, France.
Fatma Zohra KhoubaiMIRCADE Team, Univ. Bordeaux, Inserm, BMGIC, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, U1035, Bordeaux, France.
Sandrine FedouMIRCADE Team, Univ. Bordeaux, Inserm, BMGIC, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, U1035, Bordeaux, France.
Juan Carrillo-ReixachChildhood Liver Oncology Group, Germans Trias i Pujol Research Institute (IGTP), Program for Predictive and Personalized Medicine of Cancer (PMPPC), Badalona, Spain.
Stefano CarusoCentre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, INSERM, Functional Genomics of Solid Tumors Laboratory, Paris, France.
Alvaro Del Rio-AlvarezChildhood Liver Oncology Group, Germans Trias i Pujol Research Institute (IGTP), Program for Predictive and Personalized Medicine of Cancer (PMPPC), Badalona, Spain.
Emeric DuboisMontpellier GenomiX, University of Montpellier, CNRS, INSERM, Montpellier, France.
Christophe AvignonDepartment of Pathology, Bicêtre University Hospital, University of Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
Nathalie Dugot-SenantPlateforme d'histopathologie Inserm, US 005 - UMS3427 - TBMCore, Bordeaux, France.
Catherine GuettierDepartment of Pathology, Bicêtre University Hospital, University of Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
Charlotte MussiniDepartment of Pathology, Bicêtre University Hospital, University of Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
Jessica Zucman-RossiCentre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, INSERM, Functional Genomics of Solid Tumors Laboratory, Paris, France.
Carolina ArmengolChildhood Liver Oncology Group, Germans Trias i Pujol Research Institute (IGTP), Program for Predictive and Personalized Medicine of Cancer (PMPPC), Badalona, Spain.
Pierre ThiébaudMIRCADE Team, Univ. Bordeaux, Inserm, BMGIC, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, U1035, Bordeaux, France.
Philippe VeschambreMIRCADE Team, Univ. Bordeaux, Inserm, BMGIC, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, U1035, Bordeaux, France.
Christophe François GrossetMIRCADE Team, Univ. Bordeaux, Inserm, BMGIC, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, U1035, Bordeaux, France.
Université de Bordeaux · FRInserm · FRUniversité Paris-Saclay · FRCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESCentre National de la Recherche Scientifique · FRInstitute of Predictive and Personalized Medicine of Cancer · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hepatocellular carcinoma and hepatoblastoma are two liver cancers characterized by gene deregulations, chromosomal rearrangements, and mutations in Wnt/beta-catenin (Wnt) pathway-related genes. LHX2, a transcriptional factor member of the LIM homeobox gene family, has important functions in embryogenesis and liver development. LHX2 is oncogenic in many solid tumors and leukemia, but its role in liver cancer is unknown. Methods: We analyzed the expression of Results: We found a strong connection between LHX2 downregulation and Wnt activation in these two liver cancers. In hepatoblastoma, LHX2 downregulation correlated with multiple poor outcome parameters including higher patient age, intermediate- and high-risk tumors, and low patient survival. Forced expression of LHX2 reduced the proliferation, migration, and survival of liver cancer cells in vitro through the inactivation of MAPK/ERK and Wnt signals. In vivo, LHX2 impeded the development of tumors in chick embryos and repressed the Wnt pathway in Conclusion: Collectively, our findings demonstrate a tumor suppressive function of LHX2 in adult and pediatric liver cancers.

Indexed as

HepatoblastomaHepatocellular carcinomaLHX2MAPK/ERK pathwayWnt pathway

Identifiers

PMID35634422
PMCPMC9109075
OpenAlexW4200327429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.